Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel N. Chicoine	4,113,511	91,743	97.8%	2.2%
Anthony E. Dobranowski	3,549,815	655,439	84.4%	15.6%
John C. London	3,550,494	654,760	84.4%	15.6%
Deborah Shannon-Trudeau	4,115,644	89,610	97.9%	2.1%
Serge Verreault	3,550,534	654,720	84.4%	15.6%

Appointment of External Auditors

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Ernst & Young LLP reappointed	4,965,906	47,466	99.1%	0.9%

Consideration of a Special Resolution Approving a Change of the Municipality of Crescita’s Registered Office

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	AGAINST	FOR	AGAINST
Change of municipality approved	4,181,460	23,794	99.4%	0.6%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.